Making An Impact
Protecting Piglets from PEDv
When an outbreak of porcine epidemic diarrhea virus killed millions of piglets in the U.S. in 2013, Zoetis developed and was granted a conditional license from the U.S. Department of Agriculture (USDA) for a vaccine in only 14 months to help pork producers and swine veterinarians protect healthy pregnant female pigs from this devastating disease.
Fighting Schmallenberg Virus in Cattle and Sheep
In 2014, the European Medicines Agency granted Zoetis marketing authorization for Zulvac® SBV, the first centrally authorized vaccine to help control Schmallenberg virus. First identified in late 2011 in Germany and subsequently in eight countries, the virus infects cattle, sheep and goats causing fever, diarrhea, and reduced milk yield in adult animals. In pregnant animals, it can infect the nervous system of the fetus, causing brain damage and skeletal defects. With the recent re-emergence of the disease, Zulvac SBV remains the only centrally authorized vaccine available to help control it.
Combating the Largest Recent Outbreak of Bird Flu in the U.S.
An outbreak of a new strain of highly pathogenic avian influenza caused the death of more than 50 million turkeys and chickens in the U.S. in spring 2015. Working with the USDA on a rationally designed vaccine using our proprietary technology, Zoetis quickly developed a new vaccine, received a USDA conditional license in March 2016, and was awarded a contract to supply the National Veterinary Stockpile.
Defending Horses and People from Hendra Virus
In 2012, Zoetis became the first and only company to receive approval in Australia for a vaccine – Equivac® HeV to protect horses from Hendra virus, a zoonotic disease identified in the state of Queensland. The virus not only threatens the lives of horses, but also people who come in contact with infected horses.
First to Respond to a New Outbreak of Influenza in Dogs
In 2015, Zoetis quickly mobilized to fight the newly identified canine influenza virus H3N2, which began in Chicago during March and rapidly spread to 25 U.S. states. Zoetis was first to receive a conditional license from USDA in November 2015 to help veterinarians protect dogs from infection. Zoetis has since begun to market its Vanguard® CIV H3N2/H3N8, a bivalent canine flu vaccine with demonstrated safety and efficacy for protection against both highly contagious H3N2 and H3N8 strains of canine influenza virus (CIV) prevalent in the U.S.
Developing a Vaccine to Control Outbreaks of Lumpy Skin Disease in Cattle
Zoetis is participating in the DEFEND research consortium to develop a novel, subunit vaccine to help control outbreaks of lumpy skin disease (LSD) in Europe and neighboring countries. The vaccine will be specifically designed not only to protect cattle against this devastating disease but also to advance efforts to eradicate the disease by making it possible to distinguish vaccinated cattle from those infected with the natural LSD virus. LSD is an immediate and serious threat to cattle in Europe and eastern and central Asia; the disease has spread steadily north over the past 20 years from Africa through the Middle East and the eastern Mediterranean region. The DEFEND research consortium, coordinated by the Pirbright Institute in the UK, has funding, in part, from the European Union’s Horizon 2020 research and innovation program.